International Journal of Cancer · 2000 · 83 citations · 21 references
MedicineMolecular BiologyOncologyMolecular OncologyMonoclonal AntibodiesTumor ImmunologyCancer Molecular DiagnosticsCancer VaccinesImmunohistochemistryTumor AntigensTumor MarkersTumor-associated AntigensCancer AntigensGene Expression SpecificityMage AntigensMonoclonal Antibodies In CancerMonoclonal Antibodies In OncologyMonoclonal Antibody RecognitionTumor Antigen IdentificationTumor Antigen Recognition
Monoclonal antibody (Mab) 57B, which was raised against a recombinant MAGE-A3 protein, was tested for its ability to stain cells expressing various members of the MAGE-A gene family. COS-7 cells transfected with cDNAs encoding MAGE-A1, A2, A3, A4, A6, or A12 were stained, whereas those transfected with MAGE-A8, A9, A10, or A11 cDNAs were not. However, in tissue sections, we observed a different pattern of staining: the antibody effectively stained the tumors that expressed MAGE-A4 and only these tumors, regardless of the expression of the other MAGE-A genes. It seems, therefore, that at the level of MAGE gene expression found in tumors, a level clearly lower than that observed in transfected COS cells, only the MAGE-A4 protein can be reliably detected. We conclude that the 57B Mab should be useful for tumor diagnosis related to therapeutic vaccination involving MAGE-A4.
21